CBER Sees Steady Increase In Emergency IND Requests – And A Big COVID Spike In FY 2020
Executive Summary
Outside the pandemic, sponsor INDs for investigational cell and gene therapies appear to be driving much of the increase, and the surging growth continues to cause workload challenges for the US FDA.